Patients want to be an integral part of drug development. Their voices have been heard on many topics ranging from the importance of Newborn Screening, choosing meaningful endpoints and meaningful symptom amelioration, to reducing the burden of clinical trials, ensuring access to the drugs they have helped bring to market, and compassionate use. For patients with rare diseases, it is especially important that this involvement takes a global approach.

Patient Worthy will be reporting on Global Innovation in Patient Advocacy, which will bring together industry representatives from ten nations, representing drug development in therapeutic areas ranging from the most common, cardiovascular disease, to the rarest gene-based diseases. In addition, patient advocacy will be represented by three patient groups from New Zealand, UK and Canada.

This event will address how to identify and include patient advocacy organizations, from the large international disease focused groups to the smallest unstructured dynamic parent representatives. The program will cover multiple approaches for integrating the patient voice from the formation of advisory boards, and patient panels to planning for patient needs.

We look forward to hearing how rules for engagement vary across the globe, and how innovation and communication can lead to successful partnerships.

To learn more and register, click here.